paroxetine has been researched along with mianserin in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.90) | 18.7374 |
| 1990's | 9 (11.69) | 18.2507 |
| 2000's | 39 (50.65) | 29.6817 |
| 2010's | 26 (33.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Buck, LB; Petrascheck, M; Ye, X | 1 |
| Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dorman, T | 1 |
| Baldwin, D; Bullock, T; Montgomery, D; Montgomery, S | 1 |
| Mertens, C; Pintens, H | 2 |
| Smith, DF | 1 |
| Hrdina, PD; Vu, TB | 1 |
| Bourin, M; Pinot, P; Redrobe, JP | 1 |
| Skarstein, J | 1 |
| Farah, A | 1 |
| Thompson, C | 1 |
| Nutt, DJ | 1 |
| Fujiseki, Y; Inagaki, C; Kinoshita, T; Okugawa, G; Omori, K; Suzukawa, J | 1 |
| Besson, A; Blier, P; de Montigny, C; Haddjeri, N | 1 |
| Benkert, O; Kohnen, R; Szegedi, A | 1 |
| Kremer, C; Quitkin, FM; Taylor, BP | 1 |
| Benkert, O; Muller, M; Szegedi, A | 1 |
| Lima, L; Urbina, M | 1 |
| Baghai, TC; Bondy, B; Minov, C; Möller, HJ; Rupprecht, R; Schüle, C; Schwarz, MJ; Zwanzger, P | 1 |
| Angus, M; Crawford, GM; Hamilton, L; Wade, A; Wilson, R | 1 |
| Anghelescu, I; Benkert, O; Klawe, C; Kohnen, R; Müller, MJ; Szegedi, A | 1 |
| Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F | 1 |
| Hale, AS | 1 |
| Kremer, C; Murphy, GM; Rodrigues, H; Schatzberg, AF | 1 |
| Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF | 1 |
| Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Grauer, MT; Holsboer, F; Uhr, M | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Lynch, A; Madjlessi, A | 1 |
| Almarza, E; Martínez, MA; Sánchez de la Torre, C | 1 |
| Knapp, M; Patel, A; Romeo, R; Thomas, C | 1 |
| Hartter, S | 1 |
| Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF | 1 |
| Dahmen, N; Kohnen, R; Müller, MJ; Rujescu, D; Stassen, HH; Szegedi, A; Tadic, A | 3 |
| Baccichet, E; Carreira, I; Lima, L; Peña, S; Urbina, M | 1 |
| Soomro, GM | 2 |
| Dayag, M; Gil-Ad, I; Levkovitz, Y; Weizman, A; Zeldich, E | 1 |
| Albertazzi, P | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Nagata, T; Nakayama, K; Ono, K | 1 |
| Terao, T | 1 |
| Conrad, R; Geiser, F; Imbierowicz, K; Liedtke, R; Wegener, I | 1 |
| Ahned, N; Pearce, S; Varas, GM | 1 |
| Blier, P; Boucher, N; de Montigny, C; Debonnel, G; Gobbi, G; Hébert, C; Turcotte, JE | 1 |
| Lazzeroni, LC; Murphy, GM; Ryan, HS; Sarginson, JE; Schatzberg, AF | 1 |
| Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
| Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Nierenberg, AA; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ | 1 |
| Fitzgerald, P; Hannon, B; Murphy, M | 1 |
| Lee, KU; Lee, YM | 1 |
| Schruers, KR; Schutters, SI; van Megen, HJ; Van Veen, JF; Westenberg, HG | 1 |
| Blum, WF; Colla, M; Daseking, E; Deuschle, M; Gilles, M; Heuser, I; Kopf, D; Krumm, B; Lederbogen, F; Schilling, C; Weber-Hamann, B; Wudy, SA | 1 |
| Fazel, M; Goldring, L; Reed, RV | 1 |
| Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E | 1 |
| Atigari, OV; Healy, D; Jabeen, Q; Kelly, AM | 1 |
| Helmreich, I; Hiemke, C; Kohnen, R; König, J; Szegedi, A; Tadić, A; Wagner, S | 1 |
| Chiu, HF; Correll, CU; Feng, L; Feng, Y; Geng, Y; Guo, T; Hu, CQ; Lai, KY; Ungvari, GS; Wang, G; Xiang, YT; Xiao, L | 1 |
| Rush, AJ | 1 |
| Datka, W; Dudek, D; Gurwitz, D; Kmiotek, K; Obuchowicz, M; Oved, K; Pilc, A; Rzezniczek, S; Shomron, N; Siwek, M | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ | 1 |
| Li, Y; Lu, X; Tao, C; Yan, W | 1 |
| Reich, A; Szepietowski, JC | 1 |
| Mai, SM; Xiang, YT; Yang, XH; Zhang, YF; Zheng, W; Zhong, HQ | 1 |
| Baldwin, DS; Everitt, H; Lipinska, G; Malizia, AL; Manson, CC; Mayers, A; Stuart, B; Wilson, S | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
13 review(s) available for paroxetine and mianserin
| Article | Year |
|---|---|
5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour.
Topics: Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Mianserin; Paroxetine; Piperidines; Serotonin Antagonists; Suicide; Suicide Prevention | 1991 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
An overview of the clinical efficacy of mirtazapine.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Deliberate self harm.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cognitive Behavioral Therapy; Continuity of Patient Care; Flupenthixol; Hospitalization; Humans; Mianserin; Paroxetine; Psychotherapy; Self-Injurious Behavior; Suicide Prevention | 2004 |
Deliberate self harm (and attempted suicide).
Topics: Antidepressive Agents, Second-Generation; Flupenthixol; Humans; Mianserin; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide, Attempted | 2005 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
[Posttraumatic stress disorder].
Topics: Adolescent; Adult; Antidepressive Agents; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cross-Cultural Comparison; Cross-Sectional Studies; Diagnosis, Differential; Eye Movement Desensitization Reprocessing; Female; Guideline Adherence; Humans; Life Change Events; Male; Mianserin; Mirtazapine; Paroxetine; Stress Disorders, Post-Traumatic | 2013 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Itch in Psoriasis Management.
Topics: Adaptation, Psychological; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Doxepin; Histamine Antagonists; Humans; Mianserin; Mirtazapine; Paroxetine; Pruritus; Psoriasis; Social Support; Thalidomide; Ultraviolet Therapy | 2016 |
Wuling Capsule for Major Depressive Disorder: A Meta-analysis of Randomised Controlled Trials.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Depressive Disorder, Major; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Sertraline; Treatment Outcome; Young Adult | 2016 |
Antidepressants for insomnia in adults.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Fluoxetine; Humans; Mianserin; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Trazodone | 2018 |
27 trial(s) available for paroxetine and mianserin
| Article | Year |
|---|---|
Sleep and paroxetine: a comparison with mianserin in elderly depressed patients.
Topics: Aged; Aging; Depressive Disorder; Double-Blind Method; Humans; Mianserin; Paroxetine; Psychiatric Status Rating Scales; Sleep | 1992 |
A double-blind, multicentre study of paroxetine and mianserin in depression.
Topics: Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Humans; Mianserin; Paroxetine; Piperidines; Psychiatric Status Rating Scales; Serotonin Antagonists | 1989 |
Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mianserin; Paroxetine; Piperidines; Psychiatric Status Rating Scales | 1988 |
[A "trouble-blind" placebo-controlled comparative study between two new antidepressive agents].
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Humans; Mianserin; Middle Aged; Paroxetine | 1998 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sexual Dysfunctions, Psychological; Treatment Outcome | 1999 |
Mirtazapine compared with paroxetine in major depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2000 |
Substance P serum levels are increased in major depression: preliminary results.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Time Factors | 2003 |
A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Fatigue; Female; Headache; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Nausea; Paroxetine; Primary Health Care; Severity of Illness Index; Sweating; Treatment Outcome | 2003 |
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Prognosis; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Treatment Outcome | 2003 |
A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents; Automobile Driving; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Reaction Time; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Stages; Surveys and Questionnaires | 2003 |
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients.
Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Apolipoproteins E; Chromatography, High Pressure Liquid; Cognition; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genotype; Geriatric Psychiatry; Humans; Male; Mianserin; Mirtazapine; Neuropsychological Tests; Paroxetine; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2003 |
Pharmacogenetics of antidepressant medication intolerance.
Topics: Aged; Alleles; Antidepressive Agents; Cytochrome P-450 CYP2D6; Cytosine; Double-Blind Method; Drug Tolerance; Female; Genetic Markers; Genotype; High-Temperature Requirement A Serine Peptidase 2; Humans; Male; Mianserin; Mirtazapine; Mitochondrial Proteins; Paroxetine; Polymorphism, Single Nucleotide; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serine Endopeptidases; Thymine | 2003 |
Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Confidence Intervals; Double-Blind Method; Ejaculation; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Sexual Dysfunction, Physiological | 2003 |
The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Primary Health Care; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome | 2004 |
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Depressive Disorder, Major; Female; Genetic Markers; Genotype; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Proportional Hazards Models; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome | 2004 |
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Gene Frequency; Genetic Linkage; Genotype; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase; Paroxetine; Polymorphism, Single Nucleotide; Sex Characteristics; Time Factors; Treatment Outcome | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
A monoamine oxidase B gene variant and short-term antidepressant treatment response.
Topics: Adult; Alleles; Antidepressive Agents; Data Interpretation, Statistical; Depressive Disorder, Major; DNA; Double-Blind Method; Female; Humans; Introns; Male; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase; Paroxetine; Psychiatric Status Rating Scales; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors | 2007 |
Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Compliance; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrochemistry; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
FKBP5 polymorphisms and antidepressant response in geriatric depression.
Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Female; Genetic Variation; Geriatrics; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Polymorphism, Genetic; Sequence Analysis, DNA; Tacrolimus Binding Proteins; Treatment Outcome | 2010 |
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Prospective Studies; Treatment Outcome; Young Adult | 2011 |
Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.
Topics: Adrenergic alpha-Antagonists; Adult; Anxiety Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Treatment Outcome | 2011 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarkers; Body Mass Index; Cyclohexanols; Depression; Female; Humans; Leptin; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Time Factors; Treatment Outcome; Up-Regulation; Venlafaxine Hydrochloride; Weight Gain; Young Adult | 2013 |
Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; ROC Curve; Time Factors; Treatment Outcome | 2015 |
Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters.
Topics: Adult; Antidepressive Agents; Clinical Decision-Making; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2015 |
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Checklist; China; Depression; Dyspepsia; Female; Hormones; Humans; Intra-Abdominal Fat; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome; Weight Loss | 2016 |
37 other study(ies) available for paroxetine and mianserin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevity; Methiothepin; Mianserin; Octopamine; Receptors, Biogenic Amine; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Antagonists; Serotonin Antagonists; Signal Transduction; Starvation | 2007 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area.
Topics: Alanine; Amphetamine; Aniline Compounds; Animals; Antidepressive Agents; Blood Platelets; Brain; Fluoxetine; Humans; Male; Methadone; Mianserin; Mirtazapine; Morpholines; Naphthalenes; Nefopam; Nomifensine; Paroxetine; Piperidines; Rabbits; Serotonin; Stereoisomerism; Tranylcypromine; Viloxazine; Zimeldine | 1986 |
Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study.
Topics: Animals; Autoradiography; Brain Chemistry; Fluoxetine; Image Processing, Computer-Assisted; Ketanserin; Male; Mianserin; Paroxetine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Up-Regulation | 1993 |
The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice.
Topics: Amitriptyline; Animals; Antidepressive Agents; Benzopyrans; Cromakalim; Desipramine; Drug Interactions; Imipramine; Locomotion; Male; Mianserin; Mice; Minoxidil; Paroxetine; Physical Exertion; Potassium Channels; Pyrroles; Swimming | 1996 |
Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Cells, Cultured; Desipramine; Dexamethasone; Gene Expression Regulation; Haloperidol; Hippocampus; Ketanserin; Mianserin; Neurons; Paroxetine; Phentolamine; Propranolol; Radioligand Assay; Rats; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; RNA, Messenger; Sulpiride; Transcription, Genetic; Tritium | 1999 |
Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain.
Topics: Adrenergic alpha-Antagonists; Animals; Drug Therapy, Combination; Male; Mianserin; Mirtazapine; Paroxetine; Piperazines; Pyramidal Cells; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statistical; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Patient Dropouts; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Serotonin transporter modulation in blood lymphocytes from patients with major depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Proteins; Depressive Disorder, Major; Down-Regulation; Female; Fluoxetine; Humans; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Neuroimmunomodulation; Paroxetine; Radioligand Assay; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Up-Regulation | 2002 |
Pharmacological heterogeneity limits antidepressant study.
Topics: Amitriptyline; Antidepressive Agents; Depressive Disorder; Humans; Mianserin; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2003 |
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Chromatography, High Pressure Liquid; Cyclohexanols; Doxepin; Drug Resistance, Multiple; Gene Expression; Injections, Subcutaneous; Kidney; Liver; Male; Mianserin; Mice; Mice, Knockout; Mirtazapine; Paroxetine; Point Mutation; Spleen; Venlafaxine Hydrochloride | 2003 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
[Gynecomastia-galactorrhea during treatment with mirtazapine].
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Galactorrhea; Gynecomastia; Humans; Hyperprolactinemia; Male; Mianserin; Mirtazapine; Paroxetine; Risk Factors | 2004 |
A comparative solid-phase extraction study for the simultaneous determination of fluvoxamine, mianserin, doxepin, citalopram, paroxetine, and etoperidone in whole blood by capillary gas-liquid chromatography with nitrogen-phosphorus detection.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chromatography, Gas; Chromatography, Liquid; Citalopram; Doxepin; Female; Fluvoxamine; Humans; Mianserin; Nitrogen; Paroxetine; Phosphorus; Reproducibility of Results; Trazodone | 2004 |
Genetics in pharmacokinetics?
Topics: Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Depressive Disorder; Dose-Response Relationship, Drug; Genotype; Humans; Mianserin; Mirtazapine; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors | 2004 |
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
Topics: Adult; Catechol O-Methyltransferase; Depressive Disorder, Major; Female; Humans; Male; Methionine; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Polymorphism, Genetic; Time Factors; Valine | 2005 |
Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Membrane; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; Kinetics; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Middle Aged; Mirtazapine; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Psychiatric Status Rating Scales; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2005 |
Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement.
Topics: Animals; Antidepressive Agents; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; JNK Mitogen-Activated Protein Kinases; Mianserin; Mice; Neuroblastoma; Neurons; Paroxetine; Rats | 2005 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Benzodiazepines; Body Weight; Bulimia; Chronic Disease; Female; Hospitalization; Humans; Mianserin; Middle Aged; Olanzapine; Paroxetine; Schizotypal Personality Disorder; Selective Serotonin Reuptake Inhibitors | 2007 |
Unusual weight fluctuation under corticosteroid and psychotropic treatment.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Aripiprazole; Body Weight; Cyclosporine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Eating; Female; Humans; Mianserin; Paroxetine; Piperazines; Prednisolone; Quinolones; Sertraline; Takayasu Arteritis | 2008 |
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.
Topics: Adult; Anorexia Nervosa; Benzodiazepines; Calcinosis; Combined Modality Therapy; Dominance, Cerebral; Humans; Life Change Events; Male; Mediodorsal Thalamic Nucleus; Mianserin; Mirtazapine; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Psychotherapy; Thalamic Diseases; Tomography, X-Ray Computed | 2008 |
A case study of delayed serotonin syndrome: lessons learned.
Topics: Adrenergic alpha-Antagonists; Aged; Assisted Living Facilities; Drug Interactions; Female; Humans; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Time Factors | 2009 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Treatment of depression as part of end-of-life care.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Carcinoma, Squamous Cell; Depression; Drug Therapy, Combination; Esophageal Neoplasms; Fatal Outcome; Female; Humans; Mianserin; Mirtazapine; Paroxetine; Terminal Care | 2008 |
Time to discontinuation among the three second-generation antidepressants in a naturalistic outpatient setting of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Female; Humans; Korea; Male; Medication Adherence; Mianserin; Middle Aged; Mirtazapine; Outpatients; Paroxetine; Retrospective Studies; Venlafaxine Hydrochloride | 2011 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Logistic Models; Male; Mianserin; Middle Aged; Mirtazapine; Obesity; Paroxetine; Psychotherapy; Young Adult | 2013 |
New onset alcohol dependence linked to treatment with selective serotonin reuptake inhibitors.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Substitution; Female; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2013 |
Isn't It About Time to Employ Measurement-Based Care in Practice?
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Paroxetine | 2015 |
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients.
Topics: Adult; Biomarkers; Cell Proliferation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Integrin beta3; Male; Mianserin; Middle Aged; Mirtazapine; Monocytes; Paroxetine; Peptide Fragments; Serotonin Plasma Membrane Transport Proteins | 2016 |
Effect of antidepressants on spatial memory deficit induced by dizocilpine.
Topics: Animals; Antidepressive Agents; Cell Count; Citalopram; Cognition; Cognitive Dysfunction; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Fluvoxamine; Hippocampus; Interneurons; Male; Maze Learning; Memory Disorders; Mianserin; Mirtazapine; Paroxetine; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Sertraline; Spatial Memory; Venlafaxine Hydrochloride | 2016 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |